NRG-GI004: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (DMMR) Metastatic Colorectal Cancer
Aims: The purpose of this study is to compare any good and bad effects of using chemotherapy alone compared to chemotherapy and an investigational new drug, Atezolizumab.
Diagnosis: Colorectal Cancer
Principal Investigator: Robert Marsh, MD
IRB Approval Number: EH18-189
Sponsor: NRG Oncology
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Suspended
NRG-GI005: Phase II/III study of Circulating tumOr DNA as a predictive BiomaRker in Adjuvant chemotherapy in stage IIA colon cancer (COBRA) (NCT # TBD)
Aims: The purpose of this study is to determine if testing for circulating tumor DNA and further chemotherapy is better or worse than the usual approach for colon cancer.
Diagnosis: Colorectal Cancer
Principal Investigator: Robert Marsh, MD
IRB
Approval Number: EH20-293
Sponsor: NRG Oncology
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes
A021502: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
Aims: The purpose of this study is to compare any good and bad effects of using chemotherapy alone compared to chemotherapy and the drug atezolizumab and to see if adding atezolizumab will reduce the chances of your cancer from coming back.
Diagnosis: Colon Cancer
Principal Investigator: Robert Marsh, MD
IRB Approval Number: EH18-329
Sponsor: Alliance in Clinical Trials in Oncology
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes
A021703: Randomized, Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Aims: The purpose of this study is see if the addition of Vitamin D3 supplements in 2 dose levels in addition to chemotherapy will reduce the chances of your cancer from growing or spreading
Diagnosis: Colon Cancer
Principal Investigator: Robert Marsh, MD
IRB Approval Number: EH20-056
Sponsor: Alliance in Clinical Trials in Oncology
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes
UC14-0594: PERIOP-FOLFIRINOX: A Pilot Trial of Perioperative Genotype-Guided Irinotecan Dosing of gFOLFIRINOX for Locally Advanced Gastreoesophageal Adenocarcinoma
Aims: TPrincipal Investigator: Robert Marsh, MD
IRB Approval Number: EH15-389
Sponsor: University of Chicago
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes
EA2165: Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High-Risk Anal Cancer
Aims: The purpose of this study is to see if Nivolumab is helpful in reducing the risk of recurrence of anal cancer.
Diagnosis: Anal Cancer
Principal Investigator: Marisa Hill, MD
IRB Approval Number: EH19-071
Sponsor: ECOG-ACRIN
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes
A221805: Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
Aims: The purpose of this study is see if duloxetine will prevent oxaliplatin chemotherapy induced peripheral neuropathy
Diagnosis: Gastrointestinal cancer
Principal Investigator: Robert Marsh, MD
IRB Approval Number: EH20-396
Sponsor: Alliance in Clinical Trials in Oncology
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes
AbbVie M16-142: CREON (pancrelipase) therapy for subjects with exocrine pancreatic insufficiency (EPI) due to pancreatic cancer: A double-blind, randomized, parallel design with 2 dose cohorts of pancrelipase in resected pancreatic cancer subjects and an open-label single dose cohort in non-resected pancreatic cancer subjects.
Aims: The purpose of this study is evaluate the effects of 2 different dose levels of pancrelipase on dietaray fat absorption.
Diagnosis: Pancreatic cancer
Principal Investigator: Lauren Wiebe, MD
IRB Approval Number: EH19-185
Sponsor: AbbVie
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes